11-haloprostane derivatives, processes for their preparation and their
use as medicinal agents
    3.
    发明授权
    11-haloprostane derivatives, processes for their preparation and their use as medicinal agents 失效
    11-卤代前驱烷衍生物,其制备方法及其作为药物的用途

    公开(公告)号:US4983629A

    公开(公告)日:1991-01-08

    申请号:US369168

    申请日:1989-06-21

    IPC分类号: C07C405/00 C07D317/20

    摘要: 11-Haloprostane derivatives of general Formula I ##STR1## wherein X is F, Cl or Br,R.sub.1 is the residue CH.sub.2 OH or ##STR2## wherein R.sub.2 means a hydrogen atom, an alkyl, cycloalkyl, aryl, phenacyl or heterocyclic residue,A is a --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--group,B is a --CH.sub.2 --CH.sub.2 -- or trans--CH.dbd.CH-- or a --C.tbd.C--group,W is an ethylenedioxymethylene group or a hydroxymethylene group,D and E together mean a direct bond orD is a C.sub.1-10 -alkylene group,E is an oxygen or sulfur atom, a direct bond, a --C.tbd.C--bond or a --CR.sub.6 .dbd.CR.sub.7 -group with R.sub.6 and R.sub.7 meaning a hydrogen atom, a chlorine atom or an alkyl group,R.sub.4 is a hydroxy group,R.sub.5 is a hydrogen atom, an alkyl, a cycloalkyl, an aryl or a heterocyclic group, andthe salts thereof with physiologically compatible bases, processes for their preparation, and use thereof as agents inhibiting gastric acid secretion.

    摘要翻译: 其中X是F,Cl或Br,R1是残基CH 2 OH或者其中R 2表示氢原子,烷基,环烷基,芳基,苯甲酰基或杂环残基 A是-CH 2 -CH 2 - 或顺式-CH = CH-基,B是-CH 2 -CH 2 - 或反式-CH = CH-或-C 3 C C基,W是亚乙二氧基亚甲基或羟基亚甲基 基团,D和E一起表示直接键合,或D表示C1-10亚烷基,E表示氧或硫原子,直接键,-C3OND C键或-CR6 = CR7-基,R6 R7表示氢原子,氯原子或烷基,R4表示羟基,R5表示氢原子,烷基,环烷基,芳基或杂环基,其盐与生理上相容的碱,工艺 用于其制备,并且其用作抑制胃酸分泌的试剂。

    Prostaglandin-I.sub.2 derivatives
    6.
    发明授权
    Prostaglandin-I.sub.2 derivatives 失效
    前列腺素I2衍生物

    公开(公告)号:US4191694A

    公开(公告)日:1980-03-04

    申请号:US928126

    申请日:1978-07-26

    摘要: Prostane derivatives of the formula ##STR1## wherein R.sub.1 is OR.sub.2 or NHR.sub.3 ;R.sub.2 is hydrogen, C.sub.1-10 alkyl, C.sub.4-10 cycloalkyl, C.sub.6-10 aryl, or a 5 or 6 membered heterocyclic ring having 1-3 hetero atoms selected from O, N and S;R.sub.3 is the residue of a hydrocarbon carboxylic or sulfonic acid of 1-15 carbon atoms;W is (a) an OH-substituted methylene group, (b) a ##STR2## wherein the OH-groups in (a) or (b) can be in the .alpha.- or .beta.-position, or (c) such a group wherein the H atom of the OH group is replaced by the residue of a hydrocarbon carboxylic or sulfonic acid of 1-15 carbon atoms or by a conventional etherifying OH-blocking group;R.sub.4 is OH or hydroxy whose H atom is replaced as defined for W; andR.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 each independently is hydrogen or alkyl of 1-5 carbon atoms; or R.sub.9 and R.sub.10 together represent a direct bond; and, when R.sub.11 is alkyl, R.sub.10 can also be chlorine;and, for a derivative wherein R.sub.2 is hydrogen, the salts thereof with physiologically compatible bases,have improved prostaglandin activity.

    摘要翻译: 其中R1为OR2或NHR3的式(Ⅰ)所示的前驱体衍生物; R2是氢,C1-10烷基,C4-10环烷基,C6-10芳基或具有1-3个选自O,N和S的杂原子的5或6元杂环; R3是1-15个碳原子的烃羧酸或磺酸的残基; W是(a)OH-取代的亚甲基,(b)其中(a)或(b)中的OH基可以是α或β-位,或(c)这样的基团 其中OH基团的H原子被1-15个碳原子的烃羧酸或磺酸的残基或通过常规的醚化OH-封闭基团取代; R4是OH或羟基,其H原子被替换为W定义; R 5,R 6,R 7,R 8,R 9,R 10和R 11各自独立地为氢或1-5个碳原子的烷基; 或R 9和R 10一起代表直接键; 当R 11为烷基时,R 10也可为氯; 并且对于其中R 2是氢的衍生物,其与生理上相容的碱的盐具有改善的前列腺素活性。

    9-fluoroprostaglandin derivatives, their preparation and use as
medicinal agents
    7.
    发明授权
    9-fluoroprostaglandin derivatives, their preparation and use as medicinal agents 失效
    9-氟前列腺素衍生物,其制备和用作药物

    公开(公告)号:US4789685A

    公开(公告)日:1988-12-06

    申请号:US4733

    申请日:1987-01-20

    摘要: 9-fluoroprostane derivatives of Formula I ##STR1## wherein R.sub.1 is CH.sub.2 OH or ##STR2## wherein R.sub.2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R.sub.1 is the residue ##STR3## wherein R.sub.3 is an acid residue or R.sub.2 and A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--,B is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C,W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the .alpha.- or .beta.- position,D and E jointly are a direct bond orD is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen or sulfur, a direct bond, --C.tbd.C-- or --CR.sub.6 .dbd.CR.sub.7 -- wherein R.sub.6 and R.sub.7 differ from each other and each is hydrogen, chlorine, or alkyl,R.sub.4 is a free or functionally modified hydroxy group, andR.sub.5 is hydrogen, an optionally substituted aliphatic group, e.g., alkyl or halosubstituted alkyl, cycloalkyl, optionally substituted aryl or a heterocyclic group, and, when R.sub.2 is H, the physiologically compatible salts thereof with bases,have valuable pharmacological properties, e.g., as luteolytics or abortifacients.

    摘要翻译: 其中R 1是CH 2 OH或其中R 2是氢,烷基,环烷基,芳基或杂环残基的式I的α-氟仿烷基衍生物。 或R1是残基,其中R3是酸残基或R2和A是-CH2-CH2-或顺式-CH = CH-,B是-CH2-CH2-,反式-CH = CH-或-C3BOND C,W是游离的或官能改性的羟基亚甲基,其中OH基可以是α或β位,D和E共同是直接键,或D是1-10的直链或支链亚烷基或亚链烯基 可以任选被氟原子取代的碳原子,E是氧或硫,直接键,-C 3 D或-CR 6 = CR 7 - ,其中R 6和R 7彼此不同,各自是氢,氯或烷基 R4是游离的或官能改性的羟基,R5是氢,任意取代的脂族基团,例如烷基或卤代取代的烷基,环烷基,任选被取代的芳基或杂环基,当R2是H时,生理上相容的盐 具有有价值的药理学性质,例如作为骨质疏松症或流产者。

    .DELTA..sup.8,9 -Prostaglandin derivatives, their preparation and use as
medicinal agents
    8.
    发明授权
    .DELTA..sup.8,9 -Prostaglandin derivatives, their preparation and use as medicinal agents 失效
    DELTA 8,9-前列腺素衍生物,其制备和用作药物

    公开(公告)号:US4560786A

    公开(公告)日:1985-12-24

    申请号:US391734

    申请日:1982-06-24

    摘要: .DELTA..sup.8,9 -Prostane derivatives of Formula I ##STR1## wherein R.sub.1 is CH.sub.2 OH or ##STR2## wherein R.sub.2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R.sub.1 is ##STR3## wherein R.sub.3 is an acid residue or R.sub.2 ; A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH;B is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C--W is a free or functionally modified hydroxymethylene group or free or functionally modified ##STR4## wherein the OH--group can be in the .alpha.-- or .beta.-- position; D and E jointly are a direct bond orD is straight chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen, sulfur, a direct bond, --C.tbd.C-- or --CR.sub.6 .dbd.CR.sub.7 --, wherein R.sub.6 and R.sub.7 differ from each other and each is hydrogen, chlorine or alkyl;R.sub.4 is free or functionally modified hydroxy andR.sub.5 is an optionally substituted aliphatic group, cycloalkyl, optionally substituted aryl, or a heterocyclic group, and when R.sub.2 is hydrogen, physiologically compatible salts thereof with bases,have valuable pharmacological properties, e.g. luteolytic and abortifacient activities.

    摘要翻译: DELTA 8,9-式I的前驱体衍生物其中R 1是CH 2 OH或其中R 2是氢,烷基,环烷基,芳基或杂环残基; 或R 1为,其中R 3为酸残基或R 2; A是-CH 2 -CH 2 - 或顺式-CH = CH; B是-CH 2 -CH 2 - ,反式-CH = CH-或-C 3BOND C-W是游离或官能改性的羟基亚甲基或游离或官能改性的“IMAGE”,其中OH-基团可以是α或β - 位置 D和E共同是直接键合,或D是可以任选被氟原子取代的1-10个碳原子的直链或支链亚烷基或亚烯基,并且E是氧,硫,直接键,-C 3 D或 -CR 6 = CR 7 - ,其中R 6和R 7彼此不同,各自为氢,氯或烷基; R4是游离的或官能改性的羟基,R 5是任选取代的脂族基,环烷基,任选取代的芳基或杂环基,当R 2是氢时,其与碱的生理上相容的盐具有有价值的药理学性质。 luteolytic和流产活动。

    9-Fluoroprostaglandin derivatives, and use as medicinal agents
    9.
    发明授权
    9-Fluoroprostaglandin derivatives, and use as medicinal agents 失效
    9-氟前列腺素衍生物,用作药物

    公开(公告)号:US4454339A

    公开(公告)日:1984-06-12

    申请号:US395448

    申请日:1982-07-06

    摘要: 9-Fluoroprostane derivatives of Formula I ##STR1## wherein R.sub.1 is CH.sub.2 OH or ##STR2## wherein R.sub.2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R.sub.1 is the residue ##STR3## wherein R.sub.3 is an acid residue or R.sub.2 and A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--,B is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C,W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the .alpha.- or .beta.-position,D and E jointly are a direct bond orD is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen or sulfur, a direct bond, --C.tbd.C-- or --CR.sub.6 .dbd.CR.sub.7 -- wherein R.sub.6 and R.sub.7 differ from each other and each is hydrogen, chlorine, or alkyl,R.sub.4 is a free or functionally modified hydroxy group, andR.sub.5 is hydrogen, an optionally substituted aliphatic group, e.g., alkyl or halosubstituted alkyl, cycloalkyl, optionally substituted aryl or a heterocyclic group, and, when R.sub.2 is H, physiologically compatible salts thereof with bases,have valuable pharmacological properties, e.g., as luteolytics or abortifacients.

    摘要翻译: 其中R 1是CH 2 OH或其中R 2是氢,烷基,环烷基,芳基或杂环残基的式I的1-氟代衍生物(Ⅰ) 或R1是残基,其中R3是酸残基或R2和A是-CH2-CH2-或顺式-CH = CH-,B是-CH2-CH2-,反式-CH = CH-或-C3BOND C,W是游离的或官能改性的羟基亚甲基,其中OH基可以是α-或β-位,D和E共同是直接键,或D是1-10的直链或支链亚烷基或亚烯基 可以任选被氟原子取代的碳原子,E是氧或硫,直接键,-C 3 D或-CR 6 = CR 7 - ,其中R 6和R 7彼此不同,各自是氢,氯或烷基 R4是游离的或官能改性的羟基,R5是氢,任意取代的脂族基团,例如烷基或卤代取代的烷基,环烷基,任选取代的芳基或杂环基,当R 2是H时,其生理上相容的盐 具有碱性,具有有价值的药理学性质,例如作为纤溶素或流产。

    Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the
preparation thereof
    10.
    发明授权
    Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof 失效
    新型1,3-苯并二恶烷庚酸衍生物及其制备方法

    公开(公告)号:US4217360A

    公开(公告)日:1980-08-12

    申请号:US2268

    申请日:1979-01-10

    摘要: 1,3-Benzodioxaneprostanoic acid compound of the formula ##STR1## wherein R.sub.1 is hydroxy, alkoxy of 1-10 carbon atoms, methylsulfamido, substituted or unsubstituted aryloxy, or O--CH.sub.2 --U--V wherein U is a direct bond, carbonyl, or carbonyloxy, and V is phenyl or phenyl substituted, e.g. by one or more of phenyl, phenoxy, alkoxy of 1-2 carbon atoms, and halogen; A is --CH.sub.2 --CH.sub.2 -- or trans --CH.dbd.CH--; B is --CH.sub.2 --CH.sub.2 -- or cis- or trans--CH.dbd.CH--; Z is hydroxymethylene or carbonyl; X Y, if Z is hydroxymethylene, is ##STR2## or, if Z is carbonyl, is ##STR3## or --CH.dbd.CH--; R.sub.2 is hydrogen or alkyl of 1-5 carbon atoms; R.sub.3 and R.sub.4 each are H, F, Cl, Br, I or CF.sub.3, CH.sub.3 or alkoxy of 1-2 carbon atoms or R.sub.3 and R.sub.4 in 6-,7-position is methylendioxy; and if R.sub.1 is hydroxy, salts thereof with pharmaceutically acceptable bases, are agents for inducing menstruation, interrupting pregnancy, inducing labor and synchronizing the sexual cycle in female mammals.

    摘要翻译: 其中R1是羟基,1-10个碳原子的烷氧基,甲基亚磺酰氨基,取代或未取代的芳氧基或O-CH2-UV,其中U是直接键,羰基或羰基氧基的1,3-苯并二恶烷庚酸化合物 ,和V是苯基或苯基取代的,例如 苯基,苯氧基,1-2个碳原子的烷氧基和一个或多个卤素; A是-CH 2 -CH 2 - 或反-CH = CH-; B是-CH 2 -CH 2 - 或顺式 - 或反式-CH = CH-; Z是羟基亚甲基或羰基; 如果Z是羟基亚甲基,X Y是或者如果Z是羰基,则是Y或CH = CH-; R2是氢或1-5个碳原子的烷基; R3和R4各自为H,F,Cl,Br,I或CF3,CH3或1-2个碳原子的烷氧基或6-7位的R3和R4是甲氧基; 并且如果R 1是羟基,则其盐与药学上可接受的碱,是诱导雌性哺乳动物诱发月经,中断怀孕,诱导劳动和同步性循环的药剂。